Monte Rosa Therapeutics (GLUE) Current Leases (2022 - 2026)

Monte Rosa Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Current Leases rose 15.99% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (up 15.99% YoY), while the FY2025 annual figure was $4.4 million, up 18.39% from the prior year.
• Current Leases was $4.5 million for Q1 2026 at Monte Rosa Therapeutics, up from $4.4 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $4.5 million in Q1 2026 to a low of $2.7 million in Q2 2022.
• Historically, Current Leases has averaged $3.5 million across 5 years, with a median of $3.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Leases retreated 6.0% in 2023, then surged 30.15% in 2024.
• A 5-year view of Current Leases shows it stood at $3.1 million in 2022, then increased by 1.12% to $3.2 million in 2023, then increased by 17.46% to $3.7 million in 2024, then grew by 18.39% to $4.4 million in 2025, then rose by 1.96% to $4.5 million in 2026.
• The last three Current Leases figures came in at $4.5 million (Q1 2026), $4.4 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.